HIV disease progression in a patient cohort treated via a clinical research network in a resource limited setting

AIDS

Volumn 19, Issue 2, 2005, Pages 169-178

  Duncombe, Chris ^a   Kerr, Stephen J ^a   Ruxrungtham, Kiat ^a,b   Dore, Gregory J ^c   Law, Matthew G ^c   Emery, Sean ^c   Lange, Joep M ^d   Phanuphak, Praphan ^a,b   Cooper, David A ^c  

^a THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^b CHULALONGKORN UNIVERSITY   (Thailand)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

CD4 lymphocyte count; Cohort studies; HIV 1; Resource limited setting; Survival analysis; Viral load

Indexed keywords

DIDANOSINE; EFAVIRENZ; HYDROXYUREA; ITRACONAZOLE; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; NUCLEOSIDE; RITONAVIR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL RESEARCH; CLINICAL TRIAL; DISEASE COURSE; FEMALE; HEALTH CARE ACCESS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INFANT; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; THAILAND; TUBERCULOSIS;

EID: 15744378534     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200501280-00009     Document Type: Article

References (31)

1. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten CA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338:853-860.
2. Law MC, Li Y, McDonald AM, Cooper DA, Kaldor JM. Estimating the population impact in Australia of improved antiretroviral treatment for HIV infection. AIDS 2000; 14:197-201.
3. Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, d'Arminio Monforte A, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003; 362:22-29.
4. Garnett GP, Bartley L, Grassly NC, Anderson RM. Antiretroviral therapy to treat and prevent HIV/AIDS in resource-poor settings. Nat Med 2002; 8:651-654.
5. Farmer P, Leandre F, Mukherjee JS, Claude M, Nevil P, Smith-Fawzi MC, et al. Community-based approaches to HIV treatment in resource-poor settings. Lancet 2001; 358:404-409.
6. World Health Organization. Scaling up antiretroviral treatment in resource-poor settings: Guidelines for a public health approach (2003 Revision). Geneva: World Health Organization; 2003. Available at: http://www.who.int/hiv/ pub/prev_care/en/arvrevision2003en.pdf (accessed 2 April 2004).
7. Thailand's response to AIDS: Building on success, confronting the future. Bangkok: The World Bank Thailand Office; 2000. Available at: http://www.worldbank.or.th/social/index.html.
8. Ainsworth M, Beyrer C, Soucat A. AIDS and public policy: the lessons and challenges of "success" in Thailand. Health Policy 2003; 64:13-37.
9. Thai Ministry of Public Health. National Guidelines for the Clinical Management of HIV Infection in Children and Adults, 6th Edn. Nonthaburi: Ministry of Public Health, Thailand; 2000.
10. Emery S, Abrams DI, Cooper DA, Darbyshire JH, Lane HC, Lundgren JD, et al. The evaluation of subcutaneous proleukin (interleukin-2) in a randomized international trial: rationale, design, and methods of ESPRIT. Control Clin Trials 2002; 23:198-220.
11. Ananworanich J, Nuesch R, Le Braz M, Chetchotisakd P, Vibhagool A, Wicharuk S, et al. Failures of 1 week on, 1 week off antiretroviral therapies in a randomized trial. AIDS 2003; 17:F33-F37.
12. Centers for Disease Control. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992; 41:1-19.
13. Egger M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360:119-129.
14. Hogg RS, Yip B, Chan KJ, Wood E, Craib KJ, O'Shaughnessy MV, et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA 2001; 286:2568-2577.
15. Mellors JW, Munoz A, Giorgi JV, Margolick JB, Tassoni CJ, Gupta P, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126:946-954.
16. Chene G, Sterne JA, May M, Costagliola D, Ledergerber B, Phillips AN, et al. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. Lancet 2003; 362:679-686.
17. Sterling TR, Chaisson RE, Moore RD. HIV-1 RNA, CD4 T-lymphocytes, and clinical response to highly active antiretroviral therapy. AIDS 2001; 15:2251-2257.
18. Cole SR, Hernan MA, Robins JM, Anastos K, Chmiel J, Detels R, et al. Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models. Am J Epidemiol 2003; 158:687-694.
19. Perez-Hoyos S, del Amo J, Muga R, del Romero J, Garcia de Olalla P, Guerrero R, et al. Effectiveness of highly active antiretroviral therapy in Spanish cohorts of HIV seroconverters: differences by transmission category. AIDS 2003; 17:353-359.
20. Harries AD, Hargreaves NJ, Kemp J, Jindani A, Enarson DA, Maher D, et al. Deaths from tuberculosis in sub-Saharan African countries with a high prevalence of HIV-1. Lancet 2001; 357:1519-1523.
21. Siriarayapon P, Yanai H, Glynn JR, Yanpaisarn S, Uthaivoravit W. The evolving epidemiology of HIV infection and tuberculosis in northern Thailand. J Acquir Immune Defic Syndr 2002; 31:80-89.
22. Hira SK, Dore GJ, Sirisanthana T. Clinical spectrum of HIV/AIDS in the Asia-Pacific region. AIDS 1998; 12 (Suppl B): S145-S154.
23. Saenghirunvattana S. CD4+ T counts with a course of antituberculosis therapy in health and HIV-infected patients. J Med Assoc Thai 1996; 79:246-248.
24. Putong NM, Pitisuttithum P, Supanaranond W, Phonrat B, Tansuphasawadikul S, Silachamroon U, et al. Mycobacertium tuberculosis infection among HIV/AIDS patients in Thailand: Clinical manifestations and outcomes. Southeast Asian J Trop Med Public Health 2002; 33:346-351.
25. Tansuphasawadikul S, Amornkul PN, Tanchanpong C, Limpakarnjanarat K, Kaewkungwal J, Likanonsakul S, et al. Clinical presentation of hospitalized adult patients with HIV infection and AIDS in Bangkok, Thailand. J Acquir Immune Defic Syndr 1999; 21:326-332.
26. UNAIDS/WHO. The WHO and UNAIDS global initiative to provide antiretroviral therapy to 3 million people with HIV/AIDS in developing countries by the end of 2005. Geneva: WHO; 2003. Available at: http://www.who.int/3by5/ publications/documents/en/3by5StrategyMakingItHappen.pdf (accessed 2 April 2004).
27. Kroon ED, Ungsedhapand C, Ruxrungtham K, Chuenyam M, Ubolyam S, Newell ME, et al. A randomized, double-blind trial of half versus standard dose of zidovudine plus zalcitabine in Thai HIV-1-infected patients (study HIV-NAT 001). HIV Netherlands Australia Thailand Research Collaboration. AIDS 2000; 14:1349-1356.
28. Cardiello PG, Samor T, Burger D, Hoetelmans R, Mahanontharit A, Ruxrungtham K, et al. Pharmacokinetics of lower doses of saquinavir soft-gel caps (800 and 1200 mg twice daily) boosted with itraconazole in HIV-1-positive patients. Antivir Ther 2003; 8:245-249.
29. Ruxrungtham K, Kroon ED, Ungsedhapand C, Teeratakulpisarn S, Ubolyam S, Buranapraditkun S, et al. A randomized, dose-finding study with didanosine plus stavudine versus didanosine alone in antiviral-naive, HIV-infected Thai patients. AIDS 2000; 14:1375-1382.
30. Ungsedhapand C, Kroon ED, Suwanagool S, Ruxrungtham K, Yimsuan N, Sonjai A, et al. A randomized, open-label, comparative trial of zidovudine plus lamivudine versus zidovudine plus lamivudine plus didanosine in antiretroviral-naive HIV-1-infected Thai patients. J Acquir Immune Defic Syndr 2001; 27:116-123.
31. Boyd MA, Aarnoutse RE, Ruxrungtham K, Stek M Jr, van Heeswijk RP, Lange JM, et al. Pharmacokinetics of indinavir/ritonavir (800/100 mg) in combination with efavirenz (600 mg) in HIV-1-infected subjects.. J Acquir Immune Defic Syndr 2003; 34:134-139.